NIH and WHI: time for a mea culpa and steps beyond

Area of Science:

• Reproductive Endocrinology
• Clinical Trials Methodology
• Public Health Policy

Background:

• The Women's Health Initiative (WHI) study's estrogen-progestin arm termination was abrupt and poorly communicated.
• Initial risk-benefit reporting for menopausal hormone therapy (MHT) was exaggerated, particularly for perimenopausal and early postmenopausal women.
• Subsequent analyses suggest a consistent negative bias in interpreting WHI results.

Purpose of the Study:

• To re-evaluate the Women's Health Initiative (WHI) findings regarding hormone replacement therapy (HRT).
• To address methodological concerns in the original WHI analysis and reporting.
• To advocate for a revised, unbiased final report based on actual study outcomes.

Main Methods:

• Critical analysis of the Women's Health Initiative (WHI) publications and data reporting.
• Examination of the aggregation of outcome data and the use of a nonvalidated "global health index".
• Review of age-specific and time-since-menopause subgroup analyses within the WHI data.

Main Results:

• The initial 2002 WHI conclusion of greater harm than benefit appears flawed due to methodological issues.
• Failure to stratify by age or time since menopause obscured potential benefits, especially for younger women.
• Estrogen-only therapy showed positive outcomes for women aged 50-60, contradicting the overall negative interpretation.

Conclusions:

• The Women's Health Initiative (WHI) investigators' interpretations and reporting of the estrogen-progestin arm require revision.
• Methodological flaws, including data aggregation and the global health index, led to biased conclusions.
• A clear, unbiased final report is needed to accurately represent WHI findings for menopausal hormone therapy (MHT) and women's health.